PE20200514A1 - Compuestos de mic-1 y usos de estos - Google Patents
Compuestos de mic-1 y usos de estosInfo
- Publication number
- PE20200514A1 PE20200514A1 PE2019002429A PE2019002429A PE20200514A1 PE 20200514 A1 PE20200514 A1 PE 20200514A1 PE 2019002429 A PE2019002429 A PE 2019002429A PE 2019002429 A PE2019002429 A PE 2019002429A PE 20200514 A1 PE20200514 A1 PE 20200514A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acid
- mic
- extension
- acid extension
- polypeptide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title 1
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000004606 Fillers/Extenders Substances 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referido a un compuesto de citocina inhibidora de macrofagos-1 (MIC-1) que comprende un polipeptido MIC-1 con una extension de aminoacidos en el N-terminal y un prolongador unido a la extension de aminoacidos, en donde dicha extension comprende de 3 a 36 residuos de aminoacidos y en donde el polipeptido MIC-1 con la extension de aminoacidos tiene un pI calculado menos que 6.5. En donde una extension de aminoacidos en el N-terminal es: SEPATCGSETPGTSESATPESGPGTSTEPS (SEQ ID NO: 223). Tambien se refiere a su uso en la prevencion y/o tratamiento de un trastorno metabolico, tal como obesidad diabetes, entre otros.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017085576 | 2017-05-23 | ||
| CN2017113335 | 2017-11-28 | ||
| PCT/EP2018/063476 WO2018215525A1 (en) | 2017-05-23 | 2018-05-23 | Mic-1 compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200514A1 true PE20200514A1 (es) | 2020-03-05 |
Family
ID=62567604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002429A PE20200514A1 (es) | 2017-05-23 | 2018-05-23 | Compuestos de mic-1 y usos de estos |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20200079829A1 (es) |
| EP (1) | EP3630805A1 (es) |
| JP (1) | JP7015322B2 (es) |
| KR (1) | KR20200010353A (es) |
| CN (1) | CN111183148A (es) |
| AU (1) | AU2018272911B2 (es) |
| BR (1) | BR112019024102A2 (es) |
| CA (1) | CA3064320A1 (es) |
| CL (1) | CL2019003441A1 (es) |
| CO (1) | CO2019013768A2 (es) |
| MA (1) | MA48956A (es) |
| MX (1) | MX2019013801A (es) |
| PE (1) | PE20200514A1 (es) |
| PH (1) | PH12019550241A1 (es) |
| RU (1) | RU2019141031A (es) |
| TW (1) | TWI710377B (es) |
| WO (1) | WO2018215525A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2017202936A1 (en) | 2016-05-24 | 2017-11-30 | Novo Nordisk A/S | Mic-1 compounds and use thereof |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| US20230210950A1 (en) | 2019-10-04 | 2023-07-06 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| CN115925994B (zh) | 2020-09-30 | 2023-09-22 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001077137A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| WO2005099746A1 (en) | 2004-04-13 | 2005-10-27 | St Vincent's Hospital Sydney Limited | Method for modulating appetite |
| US20050256576A1 (en) | 2004-05-13 | 2005-11-17 | Moskowitz Nathan C | Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs |
| ATE444306T1 (de) | 2004-05-13 | 2009-10-15 | Lilly Co Eli | Fgf-21-fusionsproteine |
| NZ553224A (en) | 2004-07-26 | 2009-05-31 | Asterion Ltd | Linkers |
| US7858338B2 (en) | 2006-10-13 | 2010-12-28 | Novo Nordisk Health Care Ag | Processing enzymes fused to basic protein tags |
| EP2185701A4 (en) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| EP2340049B1 (en) | 2008-09-12 | 2015-11-11 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| AU2010207721B2 (en) * | 2009-01-23 | 2015-03-26 | Novo Nordisk A/S | FGF21 derivatives with albumin binder A-B-C-D-E- and their use |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| CN108530543B (zh) * | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| WO2012138919A2 (en) | 2011-04-08 | 2012-10-11 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| EA201491413A1 (ru) | 2012-01-26 | 2015-03-31 | Эмджен Инк. | Полипептиды фактора роста и дифференцировки 15 (gdf-15) |
| EP2830646B1 (en) * | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EP2950807B1 (en) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| CN113527512A (zh) | 2013-07-31 | 2021-10-22 | 美国安进公司 | 生长分化因子15(gdf-15)构建体 |
| US20150056199A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| TW201613958A (en) * | 2014-06-24 | 2016-04-16 | Novo Nordisk As | MIC-1 fusion proteins and uses thereof |
| TWI681966B (zh) | 2014-12-23 | 2020-01-11 | 丹麥商諾佛 儂迪克股份有限公司 | Ｆｇｆ２１衍生物及其用途 |
| MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
| ES2968226T3 (es) | 2015-10-02 | 2024-05-08 | Univ Wuerzburg J Maximilians | GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario |
| PL3355919T3 (pl) | 2015-10-02 | 2023-03-20 | Julius-Maximilians-Universität Würzburg | Terapia skojarzona z użyciem inhibitorów ludzkiego czynnika wzrostu i różnicowania 15 (gdf-15) oraz blokerów punktów kontrolnych układu odpornościowego |
| GB201517528D0 (en) | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
| JP6946304B2 (ja) * | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| WO2017202936A1 (en) * | 2016-05-24 | 2017-11-30 | Novo Nordisk A/S | Mic-1 compounds and use thereof |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
-
2018
- 2018-05-21 TW TW107117256A patent/TWI710377B/zh active
- 2018-05-23 BR BR112019024102-7A patent/BR112019024102A2/pt not_active Application Discontinuation
- 2018-05-23 WO PCT/EP2018/063476 patent/WO2018215525A1/en active Application Filing
- 2018-05-23 PE PE2019002429A patent/PE20200514A1/es unknown
- 2018-05-23 KR KR1020197037299A patent/KR20200010353A/ko not_active Application Discontinuation
- 2018-05-23 RU RU2019141031A patent/RU2019141031A/ru unknown
- 2018-05-23 MA MA048956A patent/MA48956A/fr unknown
- 2018-05-23 MX MX2019013801A patent/MX2019013801A/es unknown
- 2018-05-23 AU AU2018272911A patent/AU2018272911B2/en not_active Ceased
- 2018-05-23 CA CA3064320A patent/CA3064320A1/en not_active Withdrawn
- 2018-05-23 JP JP2019563484A patent/JP7015322B2/ja active Active
- 2018-05-23 CN CN201880035246.9A patent/CN111183148A/zh not_active Withdrawn
- 2018-05-23 EP EP18730247.6A patent/EP3630805A1/en active Pending
- 2018-05-23 US US16/614,454 patent/US20200079829A1/en not_active Abandoned
- 2018-05-23 US US15/986,961 patent/US10398782B2/en active Active
-
2019
- 2019-11-15 PH PH12019550241A patent/PH12019550241A1/en unknown
- 2019-11-25 CL CL2019003441A patent/CL2019003441A1/es unknown
- 2019-12-06 CO CONC2019/0013768A patent/CO2019013768A2/es unknown
-
2022
- 2022-12-19 US US18/083,729 patent/US20230364248A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630805A1 (en) | 2020-04-08 |
| MA48956A (fr) | 2020-04-08 |
| WO2018215525A1 (en) | 2018-11-29 |
| US10398782B2 (en) | 2019-09-03 |
| KR20200010353A (ko) | 2020-01-30 |
| TW201900219A (zh) | 2019-01-01 |
| RU2019141031A (ru) | 2021-06-16 |
| US20200079829A1 (en) | 2020-03-12 |
| TWI710377B (zh) | 2020-11-21 |
| JP7015322B2 (ja) | 2022-02-02 |
| CA3064320A1 (en) | 2018-11-29 |
| US20230364248A1 (en) | 2023-11-16 |
| AU2018272911A1 (en) | 2019-12-19 |
| CO2019013768A2 (es) | 2020-04-01 |
| RU2019141031A3 (es) | 2021-07-16 |
| AU2018272911B2 (en) | 2022-09-08 |
| BR112019024102A2 (pt) | 2020-06-02 |
| US20180339057A1 (en) | 2018-11-29 |
| MX2019013801A (es) | 2020-01-30 |
| CN111183148A (zh) | 2020-05-19 |
| WO2018215525A8 (en) | 2020-01-02 |
| PH12019550241A1 (en) | 2020-12-07 |
| JP2020520918A (ja) | 2020-07-16 |
| CL2019003441A1 (es) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200514A1 (es) | Compuestos de mic-1 y usos de estos | |
| PE20190117A1 (es) | Compuestos de mic-1 y usos de estos | |
| PE20171058A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| PE20191203A1 (es) | Variantes de alfa-glucosidasa acida y usos de las mismas | |
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| CO6430475A2 (es) | Polipéptidos que tienen actividad de celulasa | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| CL2016001405A1 (es) | A peptide mixture | |
| AR070962A1 (es) | Uso de defensinas contra la tuberculosis | |
| MX339277B (es) | Agente inductor de inmunidad. | |
| AR100942A1 (es) | Composiciones y método para el control glucémico que comprenden albiglutida | |
| EA202190240A1 (ru) | Варианты рекомбинантного белка | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA | |
| FI3737399T3 (fi) | ATF5-peptidivariantit ja niiden käytöt | |
| AR075933A1 (es) | Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso | |
| PE20200720A1 (es) | Compuestos bifuncionales | |
| JP2017505772A5 (es) | ||
| PE20091944A1 (es) | Metodos y composiciones para el mejoramiento de las plantas | |
| ES2536238T3 (es) | Péptidos antimicrobianos | |
| AR047805A1 (es) | Gen que interviene en la resistencia a sclerotinia | |
| PE20221271A1 (es) | Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas | |
| PE20121553A1 (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria |